Live: Primary Care Update 2023 - Las Vegas (Jun 14 - 16)

Live: Primary Care Update 2023 is organized by University Learning Systems (ULS) and will be held from Jun 14 - 16, 2023 at Westgate Las Vegas Resort & Casino, Las Vegas, Nevada, United States of America.

Description:
Medical professionals interested in learning the most recent developments in drug therapy will find our Live Pharmacology CME an excellent resource. Join the ranks of the nurse practitioners, family physicians, physician assistants, and pharmacists who have been reaping the benefits of our superior pharmacology continuing medical education for more than three decades. Our small class sizes, which allow back-and-forth conversations with clinical experts from medical and pharmacy schools who encounter patients daily, will be quite enjoyable.

This conference provides 15 contact hours of pharmacy CE and  (1.5 CEU) of live AAFP/ AMA PRA Category 1 Credit™, ACPE and pharmacology CE/ CME credit over three days.

Session: 01
5 hours | June 14, 2023
Check-in and Breakfast: 7:30AM
Educational Session: 8:00AM – 1:30PM

Practical Application of the CDC Clinical Practice Guidelines for Prescribing Opioids

At the conclusion of this program, the participant will be able to:

1. Define the crucial healing objectives of 2022 Proposed CDC Recommendations/Guidelines for suggesting opioids for outpatients.
2. Define the essential principles of discomfort monitoring, consisting of meanings such as a ) addiction; b) resistance; c) dependency; d) hyperalgesia; e) allodynia.
3. State key principles for evaluating individuals hurting, recognizing threat variables as well as actions that are related to opioid misuse, abuse, as well as dependency.
4. State examples of healthy choices for handling pain, consisting of nonpharmacologic choices as well as pharmacologic (non-opioid and opioid analgesic) treatments.
5. Compare and also contrast the threats and also benefits of using opioid treatment for severe and chronic pain and state how and also when to follow up when clients are suggested opioid anaesthetics.
6. State the main qualities of individuals that would be identified as "high risk", "moderate threat", as well as "reduced danger" for continued opioid usage.
7. State how to manage people securely as well as efficiently on opioid analgesics in intense as well as chronic discomfort setups, including starting therapy, titrating, as well as stopping the use of opioid anaesthetics.
8. Contrast and compare the basic pharmacology of a) morphine; b) hydrocodone; c) hydromorphone; d) fentanyl; e) methadone; f) buprenorphine; g) tramadol; h) tapentadol.
9. Define a reasonable amount of opioids to prescribe/ give to a person with sharp pain and persistent non-cancer discomfort.
10. Describe just how to advise clients and caregivers on the safe usage of naloxone for opioid overdose.
11. State crucial academic principles that must be applied to all clients and caregivers relating to the safe use of opioid analgesics, consisting of correct storage space and disposal.

Session: 02
5 hours | Thursday June 15, 2023
Check-in and Breakfast: 7:30AM
Educational Session: 8:00AM – 1:30PM

Update in Pharmacotherapy for Weight Loss
At the conclusion of this program, the participant will be able to:

Obesity and Weight Loss : 1) Review risk factors and criteria within obesity 2) Describe appropriate patient populations for weight loss pharmacotherapy 3) Delineate key characteristics of various pharmacotherapy options (approved and off-label) 4) Apply knowledge within patient cases to select an appropriate pharmacotherapy option.  SGLT2 Inhibitors: They aren’t just for diabetes anymore– Objectives: 1) Review mechanism of action of SGLT2i agents that provide insight into diabetes and non-diabetes disease state management 2) Differentiate among currently FDA-approved SGLT2i for diabetes and non-diabetes management 3) Apply evidence to cases where SGLT2i may be appropriate for management.

Session: 03
5 hours | Friday June 16, 2023
Check-in and Breakfast: 7:30AM
Educational Session: 8:00AM – 1:30PM

Trimming the Fat Even More than Before… Updates on Dyslipidemia Treatment with a Focus on New Recommendations, Evidence, and Novel Drug Therapies 

At the conclusion of this program, the participant will be able to:
1. Evaluation of medications and way-of-life adjustments suggested for treating dyslipidemia.
2. Explain the 2018 AHA/ACC/Multisociety cholesterol standard suggestions for hypercholesterolemia.
3. Recognize LDL limits advised in the 2022 ACC Specialist Consensus Choice Path on nonstatin treatment.
4. Describe the dangers and benefits of statin therapy.
5. Definition of statin intolerance and understanding the proof sustaining the existence of the nocebo result.
6. Advise approaches to boost adherence with statin therapy.
7. Contrast and contrast the mechanisms of activity, effectiveness, and end results data for brand-new and unique nonstatin medicine therapies.
8. Lay out the evidence and function of nonstatins in dealing with clients with hypercholesterolemia.
9. Recognize recommended treatment for patients with raised triglycerides according to the 2021 ACC Specialist Consensus Decision Pathway on hypertriglyceridemia.
10. Recommend ideal medicine therapy for patients with dyslipidemia.